C([O:8][C:9](=[O:47])[CH2:10][N:11]1[C:17]2[CH:18]=[CH:19][CH:20]=[CH:21][C:16]=2[N:15]([C:22]2[CH:27]=[CH:26][CH:25]=[CH:24][CH:23]=2)[C:14](=[O:28])[CH:13]([CH2:29][C:30]2[C:38]3[C:33](=[CH:34][CH:35]=[CH:36][CH:37]=3)[N:32]([C:39](OC(C)(C)C)=O)[N:31]=2)[C:12]1=[O:46])C1C=CC=CC=1>C(OCC)(=O)C.[Pd]>[CH3:39][N:32]1[C:33]2[C:38](=[CH:37][CH:36]=[CH:35][CH:34]=2)[C:30]([CH2:29][CH:13]2[C:12](=[O:46])[N:11]([CH2:10][C:9]([OH:47])=[O:8])[C:17]3[CH:18]=[CH:19][CH:20]=[CH:21][C:16]=3[N:15]([C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][CH:27]=3)[C:14]2=[O:28])=[N:31]1tert-butyl 3-({1-[2-(benzyloxy)-2-oxoethyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H -1,5-benzodiazepin-3-yl}methyl)-1H-indazole-1-carboxylate (0.6 g, 0.95 mM) were dissolved in 10 ml of ethyl acetate and 50 mg of 10% Pd/C were added. Reaction mixture was hydrogenated at atm. Pressure overnight. Catalyst was removed by filtration and was solvent evaporated under reduced pressure. 0.44 g of product was obtained.
読み込み中…